CHROMID® P.aeruginosa Agar

Chromogenic medium for direct ID of Pseudomonas aeruginosa

Deliver rapid direct identification of Pseudomonas aeruginosa to contribute to early intervention and better patient management

  • Direct identification of Pseudomonas aeruginosa
  • 24-hour incubation*
  • Patented chromogenic medium provides specific coloration for clear identification
  • High medical value for monitoring cystic fibrosis patients

*Depending on sample. Some samples may take longer.

 

Add to your selection

Do you need more information?

Pseudomonas aeruginosa, the most pathogenic species of the Pseudomonas genus, is generally considered to be opportunistic. It is particularly known to infect the lungs of cystic fibrosis patients and is prevalent among other immunocompromised or weakened patients, such as those suffering from burns, cancer, HIV or those in intensive care. Multi-drug resistant strains are emerging, so early detection and treatment of P. aeruginosa infection is essential.

Clear identification

The easy-to-use CHROMID® range of chromogenic media offers rapid and reliable detection and identification of microorganisms. With CHROMID® P. aeruginosa, clear, direct identification of Pseudomonas aeruginosa is possible in within 24 hours based on specific violet coloration of amino-peptidase-producing colonies.

 

Rapid identification of P. aeruginosa with the CHROMID® range

Cystic fibrosis patient monitoring

In the case of cystic fibrosis patients, effective monitoring of bacterial colonization of the respiratory tract is an essential measure for disease management. CHROMID® P. aeruginosa offers improved recognition of bacteria that often appear atypical on conventional media1. Rapid microbial detection and adapted antimicrobial treatment of P. aeruginosa, before its conversion to a mucoid phenotype which can potentially lead to chronic infection, have been shown to contribute to increased quality of life and extended life expectancy2,3.

1) Laine, L. et. al. A novel chromogenic medium for isolation of Pseudomonas aeruginosa from the sputa of cystic fibrosis patients. Journal of Cystic Fibrosis, 8:2009;143–149.

2) Newborn screening for cystic fibrosis: Evaluation of benefits and risks and recommendations for state newborn screening programs. CDC October 15, 2004/53(RR13);1-36.

3) Saiman, L., Siegel, J. Infection Control in Cystic Fibrosis. Clinical Microbiology Reviews, Jan. 2004;57–71 Vol. 17, No. 1.

CHROMID® P. aeruginosa

43462 20 x 90 mm

 

  1. Laine, L. et. al. A novel chromogenic medium for isolation of Pseudomonas aeruginosa from the sputa of cystic fibrosis patients. Journal of Cystic Fibrosis, 8:2009;143–149.
  2. Newborn screening for cystic fibrosis: Evaluation of benefits and risks and recommendations for state newborn screening programs. CDC October 15, 2004/53(RR13);1-36.
  3. Saiman, L., Siegel, J. Infection Control in Cystic Fibrosis. Clinical Microbiology Reviews, Jan. 2004;57–71 Vol. 17, No. 1.

Please consult your local bioMérieux representative for product availability in your country

Pioneering diagnostics